Savient Pharmaceuticals, Inc. (SVNTQ) - OTCPK - Limited
SVNTQ is defunct.
  • Dec. 11, 2013, 7:32 AM
    • Bankrupt Savient Pharmaceuticals (SVNTQ) has agreed to sell substantially all of its assets to Crealta Pharmaceuticals for $120.4M.
    • The figure is more than double the stalking horse bid of $55M made by Sloan Holdings.
    • The assets include Krystexxa, Savient's uric acid-specific enzyme for treating chronic gout.
    • The transaction is subject to approval by the bankruptcy court, which is due to hold a hearing about the agreement on Friday. (PR)
    | Dec. 11, 2013, 7:32 AM | 1 Comment
  • Feb. 1, 2012, 10:48 AM
    Savient Pharmaceuticals (SVNT -12.6%) shares plunge after Dendreon (DNDN +4.6%) swipes its CEO, as John Johnson will take the helm at DNDN on June 30 after only one year at SVNT. Deutsche Bank says Johnson has a history of M&A and his fresh perspective might benefit DNDN's near-term strategy, noting his success in selling Imclone to Eli Lilly and attempts to sell SVNT.
    | Feb. 1, 2012, 10:48 AM | 1 Comment
Company Description
Sector: Healthcare
Industry: Biotechnology
Country: United States